AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22023069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc 250mg administered concurrently with cephalexin 500mg
Number of subjects: 12
Study 22023069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc 250mg administered 3h before cephalexin 500mg
Number of subjects: 12
Study 22023069 — intervention group
Group type: COMPARATOR
Intervention: Zinc 250mg administered 3h after cephalexin 500mg
Number of subjects: 12
Study 22023069 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 500mg alone
Number of subjects: 12
Study 19935771 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) plus weekly paclitaxel
Number of subjects: 47
Study 19935771 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 47
Study 18416586 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alpha-2a 180 microg once weekly plus ribavirin 15 mg/kg/day
Number of subjects: 108
Study 18416586 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon-alpha-2b 1.5 microg/kg once weekly plus ribavirin 15 mg/kg/day
Number of subjects: 108
Study 15948518 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide tooth bleaching gel delivered on polyethylene film (HP)
Number of subjects: 59
Study 15948518 — intervention group
Group type: COMPARATOR
Intervention: 18% carbamide peroxide brush-applied liquid gel (CP)
Number of subjects: 59
Study 15948518 — intervention group
Group type: EXPERIMENTAL
Intervention: L*a*b* values from ShadeVision System for HP
Number of subjects: 59
Study 14525628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 14
Study 14525628 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-face mask
Number of subjects: 14
Study 11869846 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 71
Study 11869846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 71
Study 10025296 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric care group (individual counseling and primary prevention measures, n = 267)
Number of subjects: 530
Study 10025296 — intervention group
Group type: COMPARATOR
Intervention: Control group (written instructions only, n = 263)
Number of subjects: 530
Study 10025296 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric care group
Number of subjects: 530
Study 10025296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 530
Study 10025296 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric care group and Control group
Number of subjects: 530
Study 8142098 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge Sprotte needle
Number of subjects: 375
Study 8142098 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge Sprotte needle
Number of subjects: 375
Study 3124203 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic information and advice to quit smoking
Number of subjects: 309
Study 3124203 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinic information and advice to quit plus the manual 'Freedom From Smoking in 20 Days'
Number of subjects: 309
Study 3124203 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinic information and advice to quit plus the pregnancy-specific manual 'A Pregnant Woman's Self-Help Guide to Quit Smoking'
Number of subjects: 309
Study 31015221 — intervention group
Group type: EXPERIMENTAL
Intervention: PHARMS device (intervention group)
Number of subjects: 102
Study 31015221 — intervention group
Group type: COMPARATOR
Intervention: Usual care, handwritten discharge prescription (control group)
Number of subjects: 102
Study 28550928 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 94
Study 28550928 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 94
Study 25052626 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 35
Study 23221418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia cream (EMLA)
Number of subjects: 25
Study 23221418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20934731 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil (devoid of phenolic content)
Number of subjects: 33
Study 20934731 — intervention group
Group type: EXPERIMENTAL
Intervention: Common olive oil (PC = 370 mmol/kg)
Number of subjects: 33
Study 20934731 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (PC = 825 mmol/kg)
Number of subjects: 33
Study 19332508 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of Acceptance in Carers and Teachers (PACT) workshops over 1.5 days
Number of subjects: 20
Study 19332508 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 20
Study 16461044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 43
Study 16461044 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 43
Study 14996673 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial products
Number of subjects: 238
Study 14996673 — intervention group
Group type: COMPARATOR
Intervention: Nonantibacterial products
Number of subjects: 238
Study 11787719 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk supplemented with phosphate
Number of subjects: 127
Study 11787719 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk fortified with protein, calcium, and phosphate
Number of subjects: 127
Study 11787719 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented mother's milk or preterm formula
Number of subjects: 127
Study 9259870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 25 micrograms in saline
Number of subjects: 75
Study 9259870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms in saline
Number of subjects: 75
Study 9259870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 75
Study 9259870 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 75
Study 9259870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 75
Study 9259870 — intervention group
Group type: COMPARATOR
Intervention: Plain prilocaine
Number of subjects: 75
Study 8508695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 9
Study 8508695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31016340 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced radiation dose (RD) with −20%, −40%, −57%, or −80% CT radiation dose combined with iterative model‐based reconstruction (IMR) levels 1–3
Number of subjects: 76
Study 31016340 — intervention group
Group type: COMPARATOR
Intervention: Full radiation dose (FD) with iterative reconstruction (iDose4)
Number of subjects: 76
Study 28464211 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral osteoporosis therapy (OPT)
Number of subjects: 7576
Study 28464211 — intervention group
Group type: COMPARATOR
Intervention: No osteoporosis therapy (OPT)
Number of subjects: 7576
Study 25653079 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-game based therapy (VGT) using Xbox with Kinect device for 16 sessions
Number of subjects: 22
Study 25653079 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT) for 16 sessions
Number of subjects: 22
Study 25653079 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-game based therapy (VGT)
Number of subjects: 22
Study 25653079 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 22
Study 23629984 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot exercises (n=60)
Number of subjects: 150
Study 23629984 — intervention group
Group type: EXPERIMENTAL
Intervention: Thomas crooked and elongated heel with or without arch support (n=45)
Number of subjects: 150
Study 23629984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose Schwartz insoles (n=18)
Number of subjects: 150
Study 23629984 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot exercises combined with footwear modifications (n=27)
Number of subjects: 150
Study 23629984 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=50)
Number of subjects: 150
Study 22122818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 30
Study 22122818 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (BENA) 20 mg with HCTZ 25 mg
Number of subjects: 30
Study 22122818 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (VAL) 160 mg with HCTZ 12.5 mg
Number of subjects: 30
Study 18466655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic (10 g daily)
Number of subjects: 0
Study 18466655 — intervention group
Group type: COMPARATOR
Intervention: Negative control (water)
Number of subjects: 0
Study 18466655 — intervention group
Group type: COMPARATOR
Intervention: Positive control (10 g inulin)
Number of subjects: 0
Study 16835028 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby massage for 3 months after delivery
Number of subjects: 39
Study 16835028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no baby massage)
Number of subjects: 39
Study 12757433 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-hour educational workshop with supervised hands-on practice
Number of subjects: 800
Study 12757433 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 800
Study 11860828 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (RPHA-FOBT and individual quantitative risk assessment model)
Number of subjects: 0
Study 11860828 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11860828 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 0
Study 9345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 25 mg/kg/d, followed by low-dose maintenance
Number of subjects: 292
Study 9345019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipobroman (Pi) 1.2 mg/kg/d, followed by low-dose maintenance
Number of subjects: 292
Study 9345019 — intervention group
Group type: COMPARATOR
Intervention: Both HU and Pi
Number of subjects: 292
Study 8445429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and asparaginase administered at 7-day intervals
Number of subjects: 1294
Study 8445429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and asparaginase with no maintenance therapy
Number of subjects: 1294
Study 8445429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and asparaginase intensification
Number of subjects: 1294
Study 3756365 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IV Metoclopramide (total dose: 0.8 mg/kg)
Number of subjects: 36
Study 3756365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metoclopramide plus Nortriptyline (2 X 50 mg PO) plus Thiethylperazine (3 X 10 mg IV)
Number of subjects: 36
Study 3756365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metoclopramide plus Nortriptyline plus Thiethylperazine
Number of subjects: 36
Study 30388029 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 576
Study 30388029 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 576
Study 30388029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methylphenidate and behavior therapy
Number of subjects: 576
Study 30388029 — intervention group
Group type: COMPARATOR
Intervention: Community care
Number of subjects: 576
Study 27079434 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 120 mg/day
Number of subjects: 187
Study 27079434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 27079434 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 40-120 mg/day
Number of subjects: 187
Study 27079434 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 80-120 mg/day
Number of subjects: 187
Study 25172379 — intervention group
Group type: EXPERIMENTAL
Intervention: BRADA diet (Brazilian Dietary Approach to Break Hypertension), orientation and planned monthly menus, duration 6 months
Number of subjects: 206
Study 25172379 — intervention group
Group type: COMPARATOR
Intervention: Standard care focused on salt intake reduction
Number of subjects: 206
Study 23759039 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg as a bolus
Number of subjects: 205
Study 23759039 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 20 mg infused over 15 min
Number of subjects: 205
Study 23759039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bolus and infusion)
Number of subjects: 205
Study 20726279 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (ESZ) 3 mg
Number of subjects: 60
Study 20726279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17653697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 20 mg (GBX20)
Number of subjects: 40
Study 17653697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 40
Study 17653697 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 40
Study 15515282 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational tool for oral care guidelines
Number of subjects: 0
Study 11134429 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement intervention in NICUs (6 NICUs for infection, 4 NICUs for chronic lung disease)
Number of subjects: 3656
Study 11134429 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 NICUs)
Number of subjects: 3656
Study 11134429 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement intervention
Number of subjects: 3656
Study 9555556 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 146
Study 9555556 — intervention group
Group type: EXPERIMENTAL
Intervention: Raz modification
Number of subjects: 146
Study 9555556 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal Burch
Number of subjects: 146
Study 7931653 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day protocol with 8 mCi of tetrofosmin
Number of subjects: 55
Study 7931653 — intervention group
Group type: COMPARATOR
Intervention: Two-day protocol with 8 mCi of tetrofosmin followed by 24 mCi
Number of subjects: 55
Study 2466024 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch‐pentoxifylline (HAES‐steril/Trental)
Number of subjects: 394
Study 2466024 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch‐pentoxifylline‐naftidrofuryl (HAES‐steril/Trental/Dusodril)
Number of subjects: 394
Study 2466024 — intervention group
Group type: EXPERIMENTAL
Intervention: dextran‐pentoxifylline (Rheomacrodex/Trental)
Number of subjects: 394
Study 2466024 — intervention group
Group type: COMPARATOR
Intervention: placebo therapy control group (normal saline)
Number of subjects: 394
Study 31590108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (cooling hands and feet with crushed ice during paclitaxel treatment)
Number of subjects: 42
Study 31590108 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care without cryotherapy)
Number of subjects: 42
Study 29435591 — intervention group
Group type: COMPARATOR
Intervention: SRRI
Number of subjects: 460
Study 29435591 — intervention group
Group type: COMPARATOR
Intervention: SRRI + ETOH
Number of subjects: 460
Study 29435591 — intervention group
Group type: EXPERIMENTAL
Intervention: SRRI + ETOH + THC
Number of subjects: 460
Study 27821917 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation therapy (two types of rehabilitation programs, four times per week for eight weeks)
Number of subjects: 16
Study 27821917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active rehabilitation therapy)
Number of subjects: 16
Study 27821917 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation therapy
Number of subjects: 16
Study 24791863 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate (SF; Seretide, GlaxoSmithKline) Diskus (50/500 µg twice daily)
Number of subjects: 0
Study 24791863 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide/salbutamol (IS; Combivent, Boehringer Ingelheim) MDI (42 µg/240 µg quartic daily)
Number of subjects: 0
Study 24791863 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate (SF)
Number of subjects: 0
Study 24791863 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide/salbutamol (IS)
Number of subjects: 0
Study 22331829 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 6989
Study 22331829 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6989
Study 20157179 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic presumptive treatment (PPT) followed by syndromic treatment and condom-use promotion
Number of subjects: 580
Study 20157179 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic presumptive treatment (PPT)
Number of subjects: 580
Study 20157179 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom-use promotion
Number of subjects: 580
Study 17222115 — intervention group
Group type: EXPERIMENTAL
Intervention: IvIg 2 g/kg body weight
Number of subjects: 20
Study 17222115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15804151 — intervention group
Group type: EXPERIMENTAL
Intervention: APP and CS
Number of subjects: 70
Study 15804151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (5,000,000 KIU Trasylol)
Number of subjects: 70
Study 15804151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of APP, CS, and Aprotinin
Number of subjects: 70
Study 15804151 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 70
Study 15804151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 70
Study 12584830 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenle capsule (SLC)
Number of subjects: 142
Study 12584830 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC plus benazepril
Number of subjects: 142
Study 12584830 — intervention group
Group type: COMPARATOR
Intervention: benazepril (Control)
Number of subjects: 142
Study 10613620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 to 400 mg/day
Number of subjects: 34
Study 10613620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7577277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intrathoracic block of four intercostal nerves
Number of subjects: 45
Study 7577277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic extradural infusion of bupivacaine
Number of subjects: 45
Study 7577277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous paravertebral infusion of bupivacaine
Number of subjects: 45
Study 7577277 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 1785269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical gel with 0.5 mg PGE2 (n = 116)
Number of subjects: 226
Study 1785269 — intervention group
Group type: COMPARATOR
Intervention: Vagitories containing 2.5 mg PGE2 (n = 110)
Number of subjects: 226
Study 7261924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheotomy after a variable time of intubation (Group II)
Number of subjects: 77
Study 7261924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheotomy immediately (Group III)
Number of subjects: 77
Study 7261924 — intervention group
Group type: COMPARATOR
Intervention: Long-term intubation (Group I)
Number of subjects: 77
Study 30706439 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure (8‐13 days)
Number of subjects: 112
Study 30706439 — intervention group
Group type: COMPARATOR
Intervention: Late closure (after 12 weeks)
Number of subjects: 112
Study 28314866 — intervention group
Group type: EXPERIMENTAL
Intervention: attrition plus ALA-PDT
Number of subjects: 60
Study 28314866 — intervention group
Group type: COMPARATOR
Intervention: single ALA-PDT treatment
Number of subjects: 60
Study 25468473 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0
Study 25468473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 0
Study 25468473 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone
Number of subjects: 0
Study 25468473 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study 25468473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 25468473 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 23582009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Epo (63 IU/kg)
Number of subjects: 14
Study 23582009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Epo (400 IU/kg)
Number of subjects: 14
Study 23582009 — intervention group
Group type: EXPERIMENTAL
Intervention: Putative mediators of hepcidin repression (transferrin saturation, soluble transferrin receptor, growth differentiation factor 15)
Number of subjects: 14
Study 23582009 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble hemojuvelin
Number of subjects: 14
Study 23582009 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle tissue
Number of subjects: 14
Study 21358718 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Number of subjects: 37
Study 21358718 — intervention group
Group type: COMPARATOR
Intervention: SpeediCath
Number of subjects: 37
Study 19741408 — intervention group
Group type: EXPERIMENTAL
Intervention: PHIO catheter placement
Number of subjects: 91
Study 19741408 — intervention group
Group type: COMPARATOR
Intervention: PIV catheter placement
Number of subjects: 91
Study 19741408 — intervention group
Group type: COMPARATOR
Intervention: CVC catheter placement
Number of subjects: 91
Study 17728422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) for 8 weeks, followed by citalopram if insufficient response
Number of subjects: 168
Study 17728422 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders to antidepressant treatment
Number of subjects: 168